Zimmer Stock To Go Ex-dividend Tomorrow (ZMH)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- The ex-dividend date for Zimmer Holdings (NYSE: ZMH) is tomorrow, September 25, 2012. Owners of shares as of market close today will be eligible for a dividend of 18 cents per share. At a price of $67.18 as of 9:31 a.m. ET, the dividend yield is 1.1%.

The average volume for Zimmer has been 1.2 million shares per day over the past 30 days. Zimmer has a market cap of $11.66 billion and is part of the health care sector and health services industry. Shares are up 25% year to date as of the close of trading on Friday.

Zimmer Holdings, Inc., through its subsidiaries, engages in the design, development, manufacture, and marketing of orthopedic reconstructive devices, spinal and trauma devices, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. The company has a P/E ratio of 15.6, equal to the average health services industry P/E ratio and below the S&P 500 P/E ratio of 17.7.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

TheStreet Ratings rates Zimmer as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, impressive record of earnings per share growth, increase in net income, attractive valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Zimmer Ratings Report.

See our dividend calendar or top-yielding stocks list.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Zimmer Biomet's Prognosis Is Promising

Zimmer Biomet's Prognosis Is Promising

St. Jude Buying Thoratec Could Resusitate Medtech M&As

Analysts' Actions -- AT&T, Fitbit, Netflix and More

Barbarian At The Gate: Zimmer Holdings (ZMH)

Deal Delay Minor Obstacle for Zimmer

Deal Delay Minor Obstacle for Zimmer